Health

Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases

- Key patents acquired from Bayerische Patentallianz
( PR4US.com | Press Release | 2018-11-01 18:15:12 )
Hanover, Germany, November 1, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT). miRNAs are short pieces of ncRNA native to all human cells that act as regulators of gene expression. Cardior Pharmaceuticals has developed a novel class of ncRNA-based therapeutics modulating entire disease pathways to treat diseases with a high unmet medical need.

Among the inventors of the four acquired patents is Prof. Dr. med. Thomas Thum, co-founder and CSO of Cardior. The patents were filed while he was Research Group Leader at Julius-Maximilians-University, Wuerzburg (Germany). Financial terms were not disclosed.

The acquired portfolio comprises three patents on the use of certain miRNAs for the diagnosis and treatment of heart diseases such as cardiac fibrosis and ischemia/ reperfusion injury and one patent covering a number of targets relevant for the diagnosis and treatment of ischemia/reperfusion injuries of the kidney.

“We are delighted to expand our patent portfolio beyond heart diseases,” said Dr. Claudia Ulbrich, CEO of Cardior. “The transaction strengthens our position in cardiology and also enables us to move to further disease areas in the future.”

She added that Cardior is preparing for the first clinical study of its lead candidate CDR, a synthetic antisense-oligonucleotide inhibitor of a molecular master-switch microRNA, which plays a crucial role in the development of heart failure. CDR aims to halt and reverse heart failure by acting on well-defined cellular pathways and is given by an easy route of administration. Cardior expects to initiate clinical studies in 2019.


###

About Cardior

Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Thomas Thum of Hanover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

Contact Cardior
Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str.15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@ akampion com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68


Press Information


Published by

Ines-Regina Buth
http://www.akampion.com

Contact Ines-Regina Buth


 

 

 

 

 

 

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact PR4US. We will not be able to assist you. PR4US disclaims the content included in this release.
Preparing for PR: Five Hot Tips for Startups
PR Fundamentals for Startups - MaRS Best Practices
Public Relations 101
Public Relations Strategy in Our World Today!
Introduction to Public Relations
Trends in Communicating
How to Do Marketing/PR on a Budget - CoInvent Startup Summit 2014 New York
Monika Dixon Shares PR Tips